04:47 PM EST, 01/06/2025 (MT Newswires) -- Acelyrin ( SLRN ) said Monday additional phase 2 data for its thyroid eye disease drug candidate showed a "significant" response rate in patients with multiple symptoms after receiving either 50 milligram and 25 milligram injections once a week.

The biopharmaceutical company also said patients in the 100-milligram lonigutamab dosing group reached therapeutic concentration target within a matter of days. There also were no reports of hearing loss, hyperglycemia or menstrual disorders associated with lonigutamab at any dosing level, it said.

Acelyrin ( SLRN ) expects to begin phase 3 testing of lonigutamab later this quarter, following recent discussions with the US Food and Drug Administration. Topline results from the placebo-controlled trial should be available during H2 2026, it said.

Acelyrin ( SLRN ) stock was slumping 18% in extended session